Warmly congratulate Huaier Granule on its re-inclusion in the 2019 edition of "Standard for Diagnosis and Treatment of Primary Liver Cancer"-Level 1 evidence shows that Huaier Granule treatment after hepatectomy can reduce recurrence and prolong survival.

On December 7, at the 17th National Conference on Liver Cancer, the National Health Commission officially released the "Guidelines for Diagnosis and Treatment of Primary Liver Cancer (2019 Edition)". Professor Fan Jia, academician of the Chinese Academy of Sciences and President of Zhongshan Hospital Affiliated to Fudan University, said that the diagnosis, treatment and prevention of liver cancer have developed rapidly in recent years, especially the diagnostic methods and means are becoming more and more accurate, and the sensitivity and specificity are also higher and higher. Diagnostic methods have evolved from regular-assisted diagnosis to genetic diagnosis. In terms of treatment, not only the means of surgical treatment are constantly improving, but also a variety of treatment concepts, including precision treatment, immunotherapy and targeted therapy, are gradually maturing. At the same time, the combination of different types of drugs, as well as multidisciplinary cooperation in the concept of comprehensive treatment is also constantly updated, these new drugs and new treatment concepts.Diagnosis and treatment services.Inclusion will allow patients to have more treatment options and enhance more treatment possibilities. The timely update of the "standard" will provide unified diagnosis and treatment standards to medical institutions at all levels, so that the updated diagnosis and treatment plan can be applied in China as soon as possible, so that the application of innovative tumor drugs can be standardized guidance, and better provide better quality and standardized diagnosis and treatment services for liver cancer patients.Better for liver cancer patients to provide better quality and standardized diagnosis and treatment services.

It is reported that the new "Code" pays more attention to updating based on clinical evidence-based evidence and incorporates many cutting-edge new developments, which will further promote the development of liver cancer diagnosis and treatment in China. According to reports, the new "norms" in the following five aspects have important update highlights:


Highlight one: diagnosis in line with international
In terms of liver cancer diagnosis, the new "Code" will fully refer to the 2019 version of the WHO classification system for hepatocellular carcinoma and fully integrate with international standards, with a view to further accelerating the early diagnosis rate of liver cancer in my country through system innovation, comprehensively improving the 5-year survival rate of patients, and achieving the "Healthy China 2030" The goals and requirements set forth in the Outline of the Plan.


Highlight two: early diagnosis new technology to speed up clinical application
In the past two years, the early diagnosis and detection technology of liver cancer has been further developed. "Liquid biopsy" has shown important value in early diagnosis and treatment evaluation of tumor. The new "Specification" pointed out that the liver cancer detection kit based on the circulating miRNA model has been verified by many hospitals, and has obtained the registration certificate of the three types of medical devices of the State Drug Administration, and has entered clinical application. In this regard, Professor Fan Jia, academician of the Chinese Academy of Sciences and president of Zhongshan Hospital affiliated to Fudan University, pointed out that "liver cancer is highly malignant, and many patients with liver cancer are at an advanced stage as soon as they are found, and they miss the best time for surgical treatment. Therefore, early diagnosis and early treatment, especially important. It is believed that miRNA diagnostic technology will comprehensively boost the level of early diagnosis and treatment of liver cancer in China at the operational level, and truly benefit the patient group. This year marks the 50th anniversary of the establishment of the Liver Cancer Research Institute of Fudan University (Zhongshan Hospital). The institute has been committed to the promotion and application of innovative technologies in the field of liver cancer diagnosis and treatment. As one of the pioneers in this field in China, we will closely follow the national policy, deeply cultivate the field of liver cancer research, and produce more high-quality innovative technological achievements."


Highlight three: surgical treatment upgrade
In recent years, the surgical treatment of liver cancer in China has also made significant progress. The results of a number of studies, including Chinese scholars, suggest that selected patients with portal hypertension can still undergo liver resection, and their long-term survival after surgery is better than that of other treatments. Professor Zhou Jian, vice president and director of liver surgery of Zhongshan Hospital Affiliated to Fudan University, further explained that "at present, great breakthroughs have been made in the clinical level of surgical treatment of liver cancer in China, and many patients have achieved good therapeutic results through surgery. effectively prolong the survival period. Which patients are suitable for surgery? Which are not suitable? Where is the basis of judgment? Many people in the industry have given criteria based on clinical research and practice to evaluate the degree of portal hypertension more accurately, which really helps to select patients suitable for surgical resection. The new" standard "takes the accurate evaluation of portal hypertension as one of the important criteria for screening surgical patients, which is very reasonable and widely beneficial to the patient group in clinic."


Highlight four: emphasis on systemic treatment
The systematic treatment part of the new "standard" is the focus of the update. In recent years, great breakthroughs have been made in drug research such as targeted therapy and immunotherapy. Professor Qin Shukui, director of the PLA Cancer Center of the General Hospital of the Eastern Theater of the people's Liberation Army, pointed out that "systematic treatment of liver cancer is very important for prolonging the survival of patients with advanced liver cancer. We should not only pay attention to anti-tumor treatment, but also pay attention to antiviral treatment and other liver protection treatment. The development of targeted drugs for liver cancer was once unsatisfactory, and the old drug sorafenib lasted for many years, making treatment options very limited. This dilemma has been broken. The success of the REFLECT study including a large number of Chinese patients means that the world, especially Chinese patients, has an additional treatment option for lenvatinib. Chinese experts have contributed a lot in the inclusion of patients. In addition, new advances in immunotherapy continue to appear, which has increased the possibility of multiple treatments." Based on the guidance of the new "standard", the systematic treatment incorporating the new progress will bring new hope to Chinese liver cancer patients. Professor Shen Feng of the Eastern Hepatobiliary Surgery Hospital affiliated to the Second Military Medical University pointed out, "At present, the drug treatment of liver cancer is advancing by leaps and bounds worldwide, such as the first-line drug lenvatinib that has been approved in China, the second-line drug regofenib, and foreign The second-line drug immune checkpoint inhibitors approved have been promoted and applied clinically. For example, the first-line new drug lenvatinib is suitable for unresectable Chinese liver cancer patients with stage IIb, IIIa, IIIb and Child-Pugh A liver function. Its first-line treatment effect is not inferior to sorafenib, but it has better curative effect for Chinese liver cancer patients and has better survival benefit for HBV-related liver cancer."


Highlight five: tap the potential of traditional Chinese medicine
China's traditional Chinese medicine has a long history and is a treasure worth digging. In the 2017 edition of the "Standard", it is mentioned that traditional Chinese medicine can be used to improve symptoms, improve body resistance, reduce adverse reactions and improve the quality of life. In the 2019 edition of the "Standard", there is level 1 evidence that receiving Huaier granules after hepatectomy can reduce recurrence and prolong survival, which provides strong support for the treatment of liver cancer patients with traditional Chinese medicine.
(Source: Public Number of Zhongshan Hospital Affiliated to Fudan University)